Nihal Aydemir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nihal Aydemir has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Aysel Çolak
Department of Medical Pathology, Ankara City Hospital, Bilkent, Ankara, Turkey
2 shared publications - Barış Eser
Department of Nephrology, Hitit University Faculty of Medicine, Çorum, Türkiye
2 shared publications - Huseyin Kayadibi
Department of Medical Biochemistry, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey
2 shared publications - Ibrahim Dogan
Department of Nephrology, Hitit University, Faculty of Medicine, Çorum, Turkey
2 shared publications - Alpaslan Karabulut
HİTİT ÜNİVERSİTESİ TIP FAKÜLTESİ
1 shared publication - Berkant Bebek
Department of Internal Medicine, Çorum Sungurlu State Hospital, Çorum, Türkiye
1 shared publication
Latest Publications
- Open Access
- 7 January 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 35 (1) , 32-39
Relationship of Serum Pro-Gastrin-Releasing Peptide with Kidney Fibrosis and Proteinuria
Background: Interstitial fibrosis/tubular atrophy (IFTA) plays a crucial role in the pathogenesis of chronic kidney disease. Pro-gastrin-releasing peptide (proGRP), a neuropeptide, plays a role in stimulating fibroblast activity. This study explores the association between serum proGRP levels and IFTA severity. Methods: The patient group consisted of 49 patients (23 males; mean age 44.1 ± 15 years) who underwent kidney biopsy and the control group comprised 20 healthy volunteers (8 males; mean age 43.4 ± 7.2 years). Pro-gastrin-releasing peptide was measured using a commercially available Elabscience Human Pro-Gastrin-Releasing Peptide enzyme-linked immuno sorbent assay kit. The scoring system was implemented based on the percentage of IFTA severity in kidney tissue samples. Results: Pro-gastrin-releasing peptide levels were observed to be significantly elevated in the patient group compared to the controls [30.0 (22.1-48.1) U/L vs 19.7 (15.1-30.3) U/L, (P = .004)]. A statistically significant positive correlation was identi fied between proGRP level and the presence of proteinuria (P = .012). Conclusion: The study demonstrated that proGRP levels might increase in the presence of kidney fibrosis and proteinuria. Cite this article as: Özden M, Eser B, Doğan I, et al. Relationship of serum pro-gastrin-releasing peptide with kidney fibrosis and proteinuria. Turk J Nephrol. 2026;35(1):32-39.
- 7 January 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 35 (1) , 32-39
Open AccessRelationship of Serum Pro-Gastrin-Releasing Peptide with Kidney Fibrosis and Proteinuria
Background: Interstitial fibrosis/tubular atrophy (IFTA) plays a crucial role in the pathogenesis of chronic kidney disease. Pro-gastrin-releasing peptide (proGRP), a neuropeptide, plays a role in stimulating fibroblast activity. This study explores the association between serum proGRP levels and IFTA severity. Methods: The patient group consisted of 49 patients (23 males; mean age 44.1 ± 15 years) who underwent kidney biopsy and the control group comprised 20 healthy volunteers (8 males; mean age 43.4 ± 7.2 years). Pro-gastrin-releasing peptide was measured using a commercially available Elabscience Human Pro-Gastrin-Releasing Peptide enzyme-linked immuno sorbent assay kit. The scoring system was implemented based on the percentage of IFTA severity in kidney tissue samples. Results: Pro-gastrin-releasing peptide levels were observed to be significantly elevated in the patient group compared to the controls [30.0 (22.1-48.1) U/L vs 19.7 (15.1-30.3) U/L, (P = .004)]. A statistically significant positive correlation was identi fied between proGRP level and the presence of proteinuria (P = .012). Conclusion: The study demonstrated that proGRP levels might increase in the presence of kidney fibrosis and proteinuria. Cite this article as: Özden M, Eser B, Doğan I, et al. Relationship of serum pro-gastrin-releasing peptide with kidney fibrosis and proteinuria. Turk J Nephrol. 2026;35(1):32-39.
- 10 August 2020
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 45 (5) , 567-573
Relationship between renal tubulointerstitial fibrosis and serum prolidase enzyme activity
Objectives: The severity of interstitial fibrosis/tubular atrophy (IFTA) is the most important determinant of the irreversible progression of chronic kidney disease (CKD). Prolidase is the key enzyme in collagen turnover and is associated with an extracellular matrix increase. We aimed to evaluate the relationship between the presence and degree of IFTA and serum prolidase enzyme activity (SPEA) in patients undergoing a renal biopsy. Methods: This cross-sectional study included 56 patients who underwent a renal biopsy (30 males; mean age 45.3 ± 16.8 years) and also 54 healthy volunteers (21 males; mean age 42.7 ± 8.2 years). IFTA scoring was performed on the basis of percentage of IFTA presence in renal biopsy tissues (1=50%). SPEA was measured by spectrophotometric method. Results: The proteinuria and SPEA levels of the patients were significantly higher than the controls (ps =−0.461, ps =0.274, p=0.041). Conclusion: These findings suggest that increased collagen turnover decreases over time concerning the progression of renal fibrosis. Monitoring of SPEA level may useful as a biomarker for early determination of CKD progression and severity.
- 10 August 2020
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 45 (5) , 567-573
Relationship between renal tubulointerstitial fibrosis and serum prolidase enzyme activity
Objectives: The severity of interstitial fibrosis/tubular atrophy (IFTA) is the most important determinant of the irreversible progression of chronic kidney disease (CKD). Prolidase is the key enzyme in collagen turnover and is associated with an extracellular matrix increase. We aimed to evaluate the relationship between the presence and degree of IFTA and serum prolidase enzyme activity (SPEA) in patients undergoing a renal biopsy. Methods: This cross-sectional study included 56 patients who underwent a renal biopsy (30 males; mean age 45.3 ± 16.8 years) and also 54 healthy volunteers (21 males; mean age 42.7 ± 8.2 years). IFTA scoring was performed on the basis of percentage of IFTA presence in renal biopsy tissues (1=50%). SPEA was measured by spectrophotometric method. Results: The proteinuria and SPEA levels of the patients were significantly higher than the controls (ps =−0.461, ps =0.274, p=0.041). Conclusion: These findings suggest that increased collagen turnover decreases over time concerning the progression of renal fibrosis. Monitoring of SPEA level may useful as a biomarker for early determination of CKD progression and severity.